NMD Pharma A/S: Financial statements 2017
CVR: 36899069
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK -17,857,762 and a net result of DKK -21,883,435 compared with DKK -6,872,801 the year before. Equity in the 2017 report amounted to DKK -8,733,578. The company had 13 employees in the financial year.
- Gross Profit
- DKK -17,857,762
- Profit/Loss
- DKK -21,883,435
- Equity
- DKK -8,733,578
- Total Assets
- DKK 21,338,959
- Employees
- 13
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | -17.9 mio. | -21.9 mio. | -8.7 mio. | 13 |
| 2016 | - | -6.4 mio. | -6.9 mio. | 13.1 mio. | 5 |
Official annual report
Keep an eye on NMD Pharma A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
NMD Pharma A/S has published its annual report for 2016. Gross profit came to DKK -6,371,806, and the net result was DKK -6,872,801.
As of February 15, 2017, Morten Døssing has joined the board of directors of NMD Pharma A/S.
As of February 15, 2017, Stephan Christgau has left the board of directors of NMD Pharma A/S.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 18 employees (2018). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.